Public-registry site landscape for NCT07725562, a Parkinson Disease (PD) study sponsored by Zhejiang Vimgreen Pharmaceuticals, Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07725562 (registry record) |
| Sponsor | Zhejiang Vimgreen Pharmaceuticals, Ltd. |
| Condition(s) | Parkinson Disease (PD) |
| Phase | PHASE2 / PHASE3 |
| Listed sites | 1 |
| Site countries | China |
At Xuanwu Hospital of Capital Medical University — one of the facilities listed on this trial — 2 other studies are actively recruiting Parkinson Disease (PD) patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07725562 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →